You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Participation in another clinical trial at present or within 4 weeks of study entry. There may be exceptions at the discretion of the Investigator.
Has any progressive form of MS
Hypersensitivity to the active substance, or to any of the excipients of Lemtrada®
Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study
Any disability acquired from trauma or another illness that could interfere with evaluation of disability due to MS
Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results, e.g., current peptic ulcer disease or other conditions that may predispose to hemorrhage
Known bleeding disorder (e.g,. dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand's disease, disseminated intravascular coagulation (DIC), fibrinogen deficiency, or clotting factor deficiency)
Significant autoimmune disease including but not limited to immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis
History of malignancy, except basal skin cell carcinoma
Major psychiatric disorder that is not adequately controlled by treatment
Epileptic seizures that are not adequately controlled by Treatment
Active infection, e.g., deep-tissue infection, that the Investigator considers sufficiently serious to preclude study participation
In the Investigator's opinion, is at high risk for infection (e.g., indwelling catheter, dysphagia with aspiration, decubitus ulcer, history of prior aspiration pneumonia or recurrent urinary tract infection)
Seropositivity for human immunodeficiency virus (HIV)
Infection with hepatitis C Virus
Past or present hepatitis B infection (positive hepatitis B serology)
Active infection with human cytomegaly virus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV)
Latent tuberculosis unless effective anti-tuberculosis therapy has been completed, or active tuberculosis.
Invasive fungal infections in history and at present
Cervical cytology other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV) positivity
Any other illness or infection (latent or active) that, in the Investigator's opinion, could be exacerbated by study medication
Differential blood count < lower limit of normal (LLN) at Screening
Confirmed platelet count < the LLN of the evaluating laboratory at Screening or documented at <100,000/µL within the past year on a sample without platelet clumping
Presence (i.e., above the ULN) of anti-thyroid stimulating hormone receptor antibodies (anti-TSHR) and anti-thyroid peroxidase antibody (anti-TPO)
Vaccination less than 6 weeks prior to treatment with Lemtrada.
Treatment with antineoplastic or immunosuppressive drugs within 8 weeks prior to study inclusion
Intolerance of pulsed corticosteroids, especially a history of steroid psychosis
Inability to undergo MRI with gadolinium administration
Of childbearing potential with a positive serum pregnancy test, pregnant or lactating
Female patients of childbearing potential: Unwilling to agree to use a reliable and acceptable contraceptive method (Pearl index <1) throughout the study period. These methods include: hormone releasing intrauterine device (IUD), hormonal-based contraception, surgical sterilization, abstinence, or double-barrier contraception (condom and occlusive cap [diaphragm or cervical cap combined with spermicide]).
{"Condition": ["connective tissue disorders", "illness", "steroid psychosis", "Epileptic seizures", "aspiration pneumonia", "urinary tract infection", "Intolerance", "bleeding disorder", "disseminated intravascular coagulation", "dysfibrinogenemia", "factor IX deficiency", "DIC", "rheumatoid arthritis,", "lactating", "deep-tissue infection", "hepatitis B infection", "psychiatric disorder", "Von Willebrand\u0027s disease", "infection", "Latent tuberculosis", "aspiration", "active tuberculosis", "Hypersensitivity", "fungal infections", "malignancy", "hemophilia", "Inability to undergo MRI", "MS", "psoriasis", "autoimmune disease", "dysphagia", "basal skin cell carcinoma", "Infection", "clotting factor deficiency", "pregnant", "vasculitis", "fibrinogen deficiency", "systemic lupus erythematosus", "inflammatory bowel disease", "immune cytopenias,", "decubitus ulcer"], "Device": ["indwelling catheter"], "Drug": ["study medication", "gadolinium", "Vaccination", "uppressive dru r to", "pulsed corticosteroids", "immunosuppressive drugs", "Lemtrada"], "Measurement": ["human immunodeficiency virus", "Cervical cytology", "hepatitis B serology", "platelet count", "Differential blood count", "HIV", "anti-thyroid stimulating hormone receptor antibodies (anti-TSHR)", "anti-thyroid peroxidase antibody (anti-TPO)", "serum pregnancy test"], "Mood": ["Inability to"], "Multiplier": [], "Negation": ["unless", "except", "not", "other"], "Observation": ["risk for infection", "history of"], "Person": ["Female", "childbearing potential"], "Procedure": ["treatment", "anti-tuberculosis therapy", "MRI", "Treatment"], "Qualifier": ["completed", "severe", "sample without platelet clumping", "VZV", "progressive", "recurrent", "Invasive", "human cytomegaly virus", "PAP II", "Papanicolaou", "latent", "active", "high", "HPV", "PAP I", "cervical high risk", "hepatitis C Virus", "Confirmed", "human papillomavirus", "varicella-zoster virus", "Major", "EBV", "Active", "adequately controlled", "HCMV", "exacerbated by study medication", "Epstein-Barr virus"], "ReferencePoint": ["treatment with Lemtrada", "study inclusion"], "Scope": ["dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand\u0027s disease, disseminated intravascular coagulation (DIC), fibrinogen deficiency, or clotting factor deficiency", "human cytomegaly virus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV)", "other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV)", "antineoplastic or immunosuppressive drugs", "Female patients of childbearing potential", "illness or infection", "anti-thyroid stimulating hormone receptor antibodies (anti-TSHR) and anti-thyroid peroxidase antibody (anti-TPO)", "\u003c the LLN of the evaluating laboratory at Screening or documented at \u003c100,000/\u00b5L within the past year", "indwelling catheter, dysphagia with aspiration, decubitus ulcer, history of prior aspiration pneumonia or recurrent urinary tract infection", "latent or active", "cervical high risk human papillomavirus (HPV)", "PAP I or PAP II (Papanicolaou)", "immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis"], "Temporal": ["within the past year", "within 8 weeks prior to study inclusion", "active", "at Screening", "less than 6 weeks prior to treatment with Lemtrada"], "Value": ["\u003c100,000/\u00b5L", "Participation", "Seropositivity", "\u003c the LLN of the evaluating laboratory", "Presence", "positive", "above the ULN", "positivity", "\u003c lower limit of normal (LLN)"], "Visit": []}